1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

FDA approves Lundbeck's Onfi for rare, severe epileptic seizures

 
• By Donna Young

Lundbeck and its US manufacturing partner Catalent Pharma won US FDA approval of Onfi (clobazam) as an adjunctive treatment for seizures in patients two years and up with Lennox-Gastaut syndrome, a rare but severe form of epilepsy.

Lundbeck and its US manufacturing partner Catalent Pharma won US FDA approval of Onfi (clobazam) as an adjunctive treatment for seizures in patients two years and up with Lennox-Gastaut syndrome, a rare but severe form of epilepsy.

Patients with Lennox-Gastaut, which typically is diagnosed in childhood – often persisting into adulthood – generally experience multiple types

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

More from Therapeutic Category

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.